Gilead's Trodelvy Nears EU Approval for First-Line Triple-Negative Breast Cancer
GILD sits 26% above its 52-week low of $104.46.
Summary
Gilead Sciences received a positive opinion from European regulators (CHMP of EMA) recommending marketing authorization for its drug Trodelvy. This recommendation is for its use as a first-line monotherapy for metastatic triple-negative breast cancer, a severe form of the disease. This positive regulatory step follows recent significant acquisitions and associated IPR&D charges that led to a revised full-year net loss outlook, despite strong Q1 revenue. A first-line indication for this aggressive cancer represents a material market expansion opportunity for Trodelvy, potentially boosting future revenue. The European Commission's final decision is expected later this year, and Gilead has also submitted an application to the FDA for the same indication.
At the time of this announcement, GILD was trading at $131.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $162B. The 52-week trading range was $104.46 to $157.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.